Biodegradable artery graft could revolutionize leg bypass surgery

NCT ID NCT07716020

Disease control Sponsor: Xeltis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests a new type of bypass graft made from a biodegradable polymer for people with peripheral artery disease who need leg bypass surgery. The graft is designed to restore blood flow and then gradually be replaced by the body's own tissue. The trial will enroll 15 participants across Europe to see if the graft is safe and works as intended.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a biodegradable polymer vascular conduit called the XPAD bypass conduit
What this could lead to
If successful, this could provide a new option for bypass surgery that restores blood flow and may reduce complications compared to synthetic grafts.
What could go wrong
This is a small, early feasibility study with only 15 participants, so results may not apply broadly. The conduit could fail to stay open or cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants with peripheral artery occlusion who require elective lower-limb bypass surgery 2. Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions. 3. At least 18 years of age at screening 4. Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline) 5. Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent 6. Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography 7. Life expectancy of at least 24 months Exclusion Criteria: 1. Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. 2. Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above) 3. History of acute arterial occlusion requiring an emergent intervention within the last 12 months 4. Severe chronic renal insufficiency (serum creatinine \>2.5 mg/dL) or undergoing hemodialysis 5. Previous renal transplant 6. Uncontrolled arterial hypertension (BP \>200 mmHg) at 2 successive readings 7. Uncontrolled or poorly controlled diabetes 8. Abnormal blood values that could influence participant recovery and or/ graft hemostasis 9. Reduced liver function, defined as: \>2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) \>1.5 or prothrombin time (PT) \>18 seconds 10. Any active local or systemic infection 11. Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease 12. Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically 13. Previous enrolment in this study 14. Participant is participating in another study 15. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 16. Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit Intra-operative exclusion criteria: 1\. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral arterial disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.